CClinicalTrials.gg
CompletedNCT03133858Updated Dec 13, 2021

Longitudinal Cohort Study - for the Treatment of Acute Postoperative Pain and Postoperative Delirium, Postoperative Cognitive Dysfunctions, and Chronic Pain.

An observational study in Pain, Delirium and Postoperative Cognitive Dysfunction, sponsored by Charite University, Berlin, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-13.

Sponsored by Charite University, Berlin, Germany · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

Adequate pain therapy is important aspect of perioperative care. Sequelae of inadequate pain management are patient dissatisfaction, post-operative nausea and vomiting (PONV), inadequate nutrition, lack of mobilization, and an increased risk for the development of further complications, such as postoperative delirium (POD). The use of patient-controlled analgesia (PCA) systems, which allow patients to self-administer analgesics, has improved pain management. Conventional i.v. PCA and the non-invasive administration of sufentanil sublingual tablets (ZALVISO®) are available. The aim of this investigation is to study patient controlled analgesia systems and to examine the incidence of POD, POCD and postoperative pain.

Read the detailed description

There are strong evidence-based recommendations for an appropriate assessment and treatment of postoperative pain. Due to the complex and subjective nature of pain, an adequate pain therapy is an extremely challenging task, and the under- or overdosing of analgesics are common. An inadequate pain therapy leads to patient dissatisfaction, post-operative nausea and vomiting (PONV), inadequate nutrition, lack of mobilization, and an increased risk for the development of further complications, such as postoperative delirium (POD). Other long-term consequences of an insufficient postoperative analgesia include the chronification of pain and post-traumatic stress disorder (PTSD). Conversely, excessive opioid therapy may be associated with increased risk of POD. Subsequently, patients with POD have an increased risk for the consecutive development of postoperative cognitive dysfunction (POCD). The latter is marked by a progressive and permanent loss of cognitive abilities, which can ultimately lead to dementia. The use of patient-controlled analgesia (PCA) systems, which allow patients to self-administer analgesics, has been an improvement in the prevention of under- and overdosage of analgesics. Currently, there are two systems available: Conventional i.v. PCA with patients being dependent on an i.v. line and a PCA-pump and a patient-controlled, non-invasive administration of sufentanil sublingual tablets (ZALVISO®). The aim of this investigation is to study patient controlled analgesia systems and to examine the incidence of POD, POCD and postoperative pain.

02

Conditions studied

03

In context

Delirium

1,057 studies on the registry are indexed under Delirium; 238 are open to participants now.

This study's enrollment of 80 is below the median of 200 across 418 observational studies indexed under Delirium.

Browse Delirium studies →

Lead sponsor

Charite University, Berlin, Germany is the lead sponsor of 836 studies on the registry; 129 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Male and female patients scheduled for elective surgical procedures in the fields of orthopedics, trauma surgery, gynecology, and urology, with planned patient-controlled analgesia used.

Inclusion criteria

  • Patients undergoing elective surgery with planned use of a patient-controlled analgesia system for postoperative pain therapy

Exclusion criteria

Exclusion Criteria:

  • Children (\<18 years of age),
  • Pregnancy and lactation
  • Emergency surgery
  • Accommodation in an institution due to an official or judicial order
  • Participation in other clinical studies 30 days before study inclusion and during the study period
  • Refusal of the patient
  • Chronic opioid therapy > 3 months before surgery with an oral morphine sulfate equivalent >20mg/day
  • Lacking willingness to save and hand out pseudonymized data within the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium (POD)

    The Nu-DESC (Nursing Delirium Screening Scale) and CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) will be used as scoring systems to detect POD.

    Time frame: Until the 7th postoperative day

  2. Incidence of postoperative cognitive deficit (POCD)

    The neuropsychological assessment will be performed at preoperative baseline until postoperative day 7, three-months and 1-year follow-up. In order to correct change in cognitive performance for practice effects, a group of non-surgical control subjects from the POCD Register (EA1/104/16) will also be evaluated with the cognitive test battery. The control subjects will be matched to the study group regarding health status, surgery and age.

    Time frame: Up to one year

  3. Incidence of postoperative chronic pain

    The DSF (German pain questionnaire) and Ease of Care (EOC) questionnaire will be used to assess pain.

    Time frame: Up to one year

Secondary outcomes

  1. Time until fully Mobilization (walking) after elective surgery (days)

    Time frame: Until the 7th postoperative day

  2. Time to first oral nutritional intake (days)

    Time frame: Until the 7th postoperative day

  3. Patient satisfaction

    Patient Global Assessment- patients overall satisfaction with procedure to reduce pain measured as 11-item likert scale

    Time frame: Until the 5th postoperative day

  4. Postoperative complications

    Measurement includes adverse events of pain therapy

    Time frame: Until the 7th postoperative day

  5. Pain intensity

    Numeric rating scale, mean of maximum and minimum- Course of patients pain intensity measured with 11-item likert scale

    Time frame: Until the 7th postoperative day

  6. Amount of administered analgetics

    Time frame: Until the 7th postoperative day

  7. Duration until discharge

    Time frame: Participants will be followed for the duration of hospital length of stay, an expected average of 3 weeks

  8. Costs of pain therapy

    Time frame: Participants will be followed for the duration of hospital length of stay, an expected average of 3 weeks

  9. Duration of pain therapy

    Time frame: Participants will be followed for the duration of hospital length of stay, an expected average of 3 weeks

  10. Quality of life questionnaire

    Quality of life will be measured with the EQ5D

    Time frame: 3 months and 1 year after hospital discharge

  11. Intensive care unit length of stay

    Time frame: Participants will be followed for the duration of intensive care stay, an expected average of 1 week

  12. Mortality

    Time frame: Up to one year

07

Study locations

1 site
  • Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin
    Berlin, 13353, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03133858
Lead sponsor
Charite University, Berlin, Germany
Responsible party
Claudia Spies (Head of the Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin, Charite University, Berlin, Germany) — Principal investigator
First posted
Apr 28, 2017
Start date
Nov 9, 2017
Primary completion
Dec 14, 2020
Completion
Nov 28, 2021
Last update
Dec 13, 2021

Study contacts

Claudia Spies, MD, Prof.
study director · Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion